I-III期肛管鳞状细胞癌的系统治疗:ASCO指南
该指南基于系统综述(含3项随机对照试验和3项非随机干预研究)为I-III期肛管癌的全身治疗提供循证推荐。推荐丝裂霉素C联合氟尿嘧啶类作为放化疗的放射增敏组分,顺铂联合氟尿嘧啶可作为替代方案;不推荐常规诱导化疗或放化疗后额外化疗。
要点
- 推荐丝裂霉素C联合氟尿嘧啶类(氟尿嘧啶或卡培他滨)作为肛管癌放化疗的放射增敏组分。
- 顺铂联合氟尿嘧啶可作为放射增敏化疗的额外推荐组合。
- 因丝裂霉素C骨髓抑制,免疫抑制患者首选顺铂联合氟尿嘧啶。
核心结论
- 丝裂霉素C联合氟尿嘧啶类推荐作为肛管癌放化疗的放射增敏组分;顺铂联合氟尿嘧啶为额外可推荐组合。
- 免疫抑制患者首选顺铂联合氟尿嘧啶;顺铂不推荐用于肾功能不全、显著神经病变或听力损失患者。
- 不推荐局部肛管癌患者常规进行放化疗前诱导化疗或放化疗后额外化疗。
研究设计与样本
- ASCO专家小组基于明尼苏达循证实践中心系统综述(含3项随机对照试验和3项非随机干预研究)达成共识制定本指南。
主要发现
- 系统综述包含3项随机对照试验和3项非随机干预研究,与指南主题相关并为推荐提供依据。
关键数值与推荐
- 推荐丝裂霉素C联合氟尿嘧啶类(氟尿嘧啶或卡培他滨)作为放化疗的放射增敏组分。
- 顺铂联合氟尿嘧啶可作为放射增敏化疗的额外推荐组合。
- 因丝裂霉素C相关骨髓抑制,免疫抑制患者首选顺铂联合氟尿嘧啶。
- 顺铂不推荐用于肾功能不全、显著神经病变或听力损失患者,无证据推荐用卡铂替代顺铂。
- 不推荐局部肛管癌患者常规进行放化疗前诱导化疗或放化疗后额外化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. METHODS: A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations. RESULTS: The systematic review contained three randomized controlled trials and three nonrandomized studies of interventions that were relevant to the guideline topic and informed the recommendations. RECOMMENDATIONS: Mitomycin-C (MMC) with a fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabine is often used as an orally administered alternative to FU and is currently being used in ongoing clinical trials. Cisplatin with FU is an additional chemotherapy combination that may be recommended as radiosensitizing chemotherapy. Because of the myelosuppression associated with MMC, the preferable regimen for patients with immunosuppression is cisplatin and FU. Cisplatin is not recommended for patients with renal dysfunction, significant neuropathy, or hearing loss, and there is no evidence to recommend substituting carboplatin for cisplatin. Dose and schedule options for recommended chemotherapy agents are included within the full text of the guideline. Routine induction chemotherapy before CRT and additional chemotherapy after CRT are not recommended for patients with localized anal cancer.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
引用
- Morris VK, Kennedy EB, Amin MA, et al. Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2024. PMID: 39680825. doi:10.1200/JCO-24-02120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。